| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
RBC Capital analyst Luca Issi maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Sector Perform and raises the price target ...
CRISPR Therapeutics' CTX310 trial shows strong, sustained lipid reductions and favorable safety, boosting confidence in its...
Baird analyst Jack Allen maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Neutral and lowers the price target from $52 to...
Needham analyst Gil Blum maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and lowers the price target from $81 to $80.
CRISPR Therapeutics (NASDAQ:CRSP) reported quarterly losses of $(1.17) per share which beat the analyst consensus estimate of $...
Data presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions 2025--Phase 1 clinic...
https://www.fda.gov/news-events/press-announcements/fda-awards-second-batch-national-priority-vouchers
Cathie Wood-led Ark Invest purchased shares in Bullish, a crypto exchange backed by Peter Thiel, through three of its funds. Ot...
Intellia Therapeutics (NASDAQ: NTLA) paused their Phase 3 MAGNITUDE and MAGNITUDE-2 trials after a serious liver-related advers...
